Benjamin Linas, MD
Associate Professor
Boston University School of Medicine
Dept of Medicine
Infectious Diseases

MD, New York University School of Medicine
MPH, Harvard School of Public Health



Dr. Linas is a national leader in hepatitis-C virus (HCV) infection and HCV/HIV co-infection comparative- and cost-effectiveness research using computational biology, clinical epidemiology and clinical economics methods. Dr. Linas has an excellent track record of productivity, ample funding from the NIH and CDC, and a growing core of successful trainees. Dr. Linas directs the HIV/HCV core of the Center for Health Economics of Treatment Interventions for Substance Use Disorders, HCV, and HIV, funded by the National Institute on Drug Abuse (NIDA) in collaboration with Cornell, U Penn and Miami.

Associate Professor
Boston University School of Public Health
Epidemiology





A Cluster RCT to Increase HIV Testing in Substance Use Treatment Programs
09/01/2016 - 07/31/2021 (PI)
Trustees of Columbia University NIH-NIDA

Economic Modeling for HIV, Viral Hepatitis, STD, TB and School Health
09/30/2014 - 09/29/2018 (PI)
Harvard School of Public Health CDC

Lifespan/Tufts/brown Center for AIDS Research (CFAR): Core B Developmental (Pilot Projects)
07/01/2016 - 06/30/2018 (PI)
Miriam Hospital NIH-NIAID

Health Economics of Substance Abuse and HCV/HIV Treatment in the Era of Integrated Health Care - …
09/01/2017 - 04/30/2018 (PI)
Weill Cornell Medical College NIH-NIDA

Health Economics of Substance Use Disorder, HCV, and HIV Treatment in the Era of Integrated Health..
07/01/2015 - 04/30/2018 (PI)
Cornell University NIH-NIDA

Economic Analysis of Rapid HIV and HCV Testing in Drug Abuse Treatment Programs
02/15/2015 - 01/31/2018 (PI)
Cornell University NIH-NIDA

Intensive Models of HCV Care for Injection Drug Users
07/15/2012 - 06/30/2017 (PI)
AlbertEinsteinCllgeOfMed of Yeshiva U. NIH-NIDA

Simulation Modeling to Improve HIV/HCV Screening, Treatment & Care - Supplement
06/01/2014 - 05/31/2017 (PI)
NIH-NIDA
5R01DA031059-04

Simulation Modeling to Improve HIV/HCV Screening, Treatment & Care
06/15/2012 - 05/31/2017 (PI)
NIH-NIDA
5R01 DA031059-04

TO#3 Strategic Timing of Antiretroviral Treatment (START) - INSIGHT
12/01/2010 - 05/31/2017 (PI)
Institute for Clinical Research, Inc. NIH-NIAID

Showing 10 of 14 results. Show All Results


Yr Title Project-Sub Proj Pubs
2017 Health Economics of Substance Use Disorder, HCV, and HIV Treatment in the Era of Integrated Health Care (HCV + HIV Core) 5P30DA040500-03-6229 1
2016 Health Economics of Substance Use Disorder, HCV, and HIV Treatment in the Era of Integrated Health Care (HCV + HIV Core) 5P30DA040500-02-6229 1
2015 Health Economics of Substance Use Disorder, HCV, and HIV Treatment in the Era of Integrated Health Care (HCV + HIV Core) 1P30DA040500-01-6229 1
2014 Simulation Modeling to Improve HIV/HCV Screening, Treatment and Care 3R01DA031059-03S1 13
2014 Simulation Modeling to Improve HIV/HCV Screening, Treatment and Care 5R01DA031059-03 13
2013 Simulation Modeling to Improve HIV/HCV Screening, Treatment and Care 5R01DA031059-02 13
2012 Simulation Modeling to Improve HIV/HCV Screening, Treatment and Care 1R01DA031059-01A1 13
2011 Improving HIV and HCV outcomes in U.S. AIDS Drug Assistance Programs 5K01AI073193-05 6
2010 Improving HIV and HCV outcomes in U.S. AIDS Drug Assistance Programs 5K01AI073193-04 6
2009 Improving HIV and HCV outcomes in U.S. AIDS Drug Assistance Programs 5K01AI073193-03 6
Showing 10 of 12 results. Show All Results
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

  1. Chow FC, Wilson MR, Wu K, Ellis RJ, Bosch RJ, Linas BP. Stroke incidence is highest in women and non-Hispanic blacks living with HIV in the AIDS Clinical Trials Group Longitudinal Linked Randomized Trials cohort. AIDS. 2018 Jun 01; 32(9):1125-1135. PMID: 29746317.
     
  2. Saag LA, LaValley MP, Hochberg NS, Cegielski JP, Pleskunas JA, Linas BP, Horsburgh CR. Low body mass index and latent tuberculous infection: a systematic review and meta-analysis. Int J Tuberc Lung Dis. 2018 Apr 01; 22(4):358-365.View Related Profiles. PMID: 29562981; DOI: 10.5588/ijtld.17.0558;.
     
  3. Freiman JM, Jacobson KR, Muyindike WR, Horsburgh CR, Ellner JJ, Hahn JA, Linas BP. Isoniazid Preventive Therapy for People With HIV Who Are Heavy Alcohol Drinkers in High TB-/HIV-Burden Countries: A Risk-Benefit Analysis. J Acquir Immune Defic Syndr. 2018 Apr 01; 77(4):405-412.View Related Profiles. PMID: 29239900.
     
  4. Murphy SM, Leff JA, Linas BP, Morgan JR, McCollister K, Schackman BR. Implementation of a nationwide health economic consultation service to assist substance use researchers: Lessons learned. Subst Abus. 2018 Mar 20; 1-19. PMID: 29558284.
     
  5. Chow FC, Wilson MR, Wu K, Ellis RJ, Bosch RJ, Linas BP. Stroke incidence is highest in women and non-Hispanic Blacks living with HIV in the ALLRT cohort. AIDS. 2018 Mar 15. PMID: 29547443.
     
  6. Schackman BR, Gutkind S, Morgan JR, Leff JA, Behrends CN, Delucchi KL, McKnight C, Perlman DC, Masson CL, Linas BP. Cost-effectiveness of hepatitis C screening and treatment linkage intervention in US methadone maintenance treatment programs. Drug Alcohol Depend. 2018 Apr 01; 185:411-420. PMID: 29477574.
     
  7. Akiyama MJ, Agyemang L, Arnsten JH, Heo M, Norton BL, Schackman BR, Linas BP, Litwin AH. Rationale, design, and methodology of a trial evaluating three models of care for HCV treatment among injection drug users on opioid agonist therapy. BMC Infect Dis. 2018 02 09; 18(1):74. PMID: 29426304.
     
  8. Leech AA, Bortoletto P, Christiansen C, Drainoni ML, Linas BP, Roeca C, Curtis M, Sullivan M. Assessing access to assisted reproductive services for serodiscordant couples with human immunodeficiency virus infection. Fertil Steril. 2018 Mar; 109(3):473-477.View Related Profiles. PMID: 29428310.
     
  9. Barocas JA, Tasillo A, Eftekhari Yazdi G, Wang J, Vellozzi C, Hariri S, Isenhour C, Randall L, Ward JW, Mermin J, Salomon JA, Linas BP. Population level outcomes and cost-effectiveness of expanding the recommendation for age-based hepatitis C testing in the United States. Clin Infect Dis. 2018 Feb 06. PMID: 29420742.
     
  10. Assoumou SA, Tasillo A, Leff JA, Schackman BR, Drainoni ML, Horsburgh CR, Barry MA, Regis C, Kim AY, Marshall A, Saxena S, Smith PC, Linas BP. Cost-Effectiveness of One-Time Hepatitis C Screening Strategies Among Adolescents and Young Adults in Primary Care Settings. Clin Infect Dis. 2018 Jan 18; 66(3):376-384.View Related Profiles. PMID: 29020317.
     
Showing 10 of 51 results. Show More

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 51 publications over 14 distinct years, with a maximum of 10 publications in 2018

YearPublications
19971
19981
20002
20062
20092
20101
20111
20121
20132
20148
20155
20166
20179
201810
Contact for Mentoring:


771 Albany St
Boston MA 02118
Google Map


Linas's Networks
Click the "See All" links for more information and interactive visualizations
Concepts
_
Co-Authors
_
Similar People
_
Same Department